Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jul 17 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-5.18 Insider Own21.88% Shs Outstand29.93M Perf Week16.36%
Market Cap48.04M Forward P/E- EPS next Y-1.71 Insider Trans-3.13% Shs Float29.32M Perf Month-6.57%
Income-153.05M PEG- EPS next Q-0.71 Inst Own25.03% Short Float5.52% Perf Quarter-52.24%
Sales1.76M P/S27.29 EPS this Y57.92% Inst Trans-4.57% Short Ratio2.61 Perf Half Y-49.21%
Book/sh-2.15 P/B- EPS next Y33.87% ROA-116.64% Short Interest1.62M Perf Year-88.07%
Cash/sh1.98 P/C0.65 EPS next 5Y- ROE-1766.94% 52W Range1.03 - 12.21 Perf YTD-56.61%
Dividend Est.- P/FCF- EPS past 5Y-35.97% ROI-516.70% 52W High-89.52% Beta0.32
Dividend TTM- Quick Ratio2.49 Sales past 5Y53.60% Gross Margin2.05% 52W Low23.67% ATR (14)0.13
Dividend Ex-Date- Current Ratio2.57 EPS Y/Y TTM21.90% Oper. Margin-7933.20% RSI (14)47.00 Volatility11.49% 10.62%
Employees74 Debt/Eq- Sales Y/Y TTM202.24% Profit Margin-8715.72% Recom1.80 Target Price6.30
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q52.96% Payout- Rel Volume2.75 Prev Close1.34
Sales Surprise29.33% EPS Surprise-28.91% Sales Q/Q182.52% EarningsMay 09 BMO Avg Volume621.13K Price1.28
SMA207.93% SMA50-20.18% SMA200-53.47% Trades Volume1,710,497 Change-4.48%
Date Action Analyst Rating Change Price Target Change
Feb-21-24Downgrade UBS Buy → Neutral $9 → $4
Aug-15-23Downgrade Mizuho Buy → Neutral $40 → $4
Jul-17-23Downgrade Guggenheim Buy → Neutral
Mar-10-23Downgrade Jefferies Buy → Hold $20 → $22
Dec-01-22Upgrade Goldman Sell → Neutral $16
Jul-07-22Initiated Mizuho Buy $19
Apr-06-22Reiterated BofA Securities Buy $80
Nov-15-21Downgrade Goldman Neutral → Sell $55 → $24
Apr-09-21Initiated Berenberg Buy $75
Feb-01-21Initiated UBS Buy $99
Jul-16-24 07:00AM
Jun-25-24 07:37AM
May-28-24 07:00AM
May-21-24 07:00AM
11:58AM Loading…
May-10-24 11:58AM
May-09-24 11:31PM
Apr-25-24 07:00AM
Apr-24-24 10:30AM
Apr-22-24 07:00AM
Apr-10-24 07:00AM
Mar-25-24 07:00AM
Mar-15-24 07:00AM
08:57AM Loading…
Mar-13-24 08:57AM
Mar-12-24 09:48PM
Mar-07-24 02:52PM
Mar-01-24 07:00AM
Feb-22-24 12:58PM
Feb-14-24 08:30AM
Feb-13-24 09:00AM
Feb-12-24 07:14AM
Feb-09-24 09:05AM
Feb-08-24 04:01PM
Feb-06-24 07:00AM
Feb-05-24 07:00AM
Dec-12-23 07:00AM
Dec-11-23 07:00AM
07:29PM Loading…
Dec-01-23 07:29PM
Nov-30-23 07:00AM
Nov-24-23 06:40AM
Nov-15-23 02:23PM
Nov-14-23 07:52AM
Nov-08-23 07:00AM
Nov-06-23 07:00AM
Oct-31-23 07:00AM
Oct-30-23 07:00AM
Oct-25-23 09:18AM
Oct-17-23 10:26AM
Oct-10-23 09:45AM
Oct-04-23 07:00AM
Sep-28-23 05:35PM
Aug-29-23 07:30AM
Aug-17-23 10:30AM
Aug-15-23 05:43PM
Aug-14-23 11:04PM
Jul-31-23 07:00AM
Jul-07-23 08:16AM
Jul-05-23 10:20AM
Jun-29-23 04:12PM
Jun-15-23 09:46PM
Jun-02-23 06:20AM
Jun-01-23 07:00AM
May-25-23 04:03PM
May-16-23 07:00AM
May-11-23 03:13PM
May-09-23 02:03AM
May-08-23 04:54PM
May-04-23 08:00AM
May-02-23 07:00AM
Apr-24-23 07:00AM
Mar-22-23 08:21AM
Mar-14-23 04:15PM
Mar-11-23 09:25AM
Mar-10-23 02:32AM
Mar-09-23 07:00AM
Feb-23-23 07:00AM
Feb-21-23 07:00AM
Feb-14-23 09:50AM
Feb-13-23 05:00PM
Feb-08-23 02:27PM
Jan-27-23 07:00AM
Jan-11-23 07:00AM
Dec-27-22 07:34AM
Dec-22-22 07:00AM
BioXcel Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of artificial intelligence solutions in neuroscience and immuno-oncology. It also focuses on utilizing technology and research to develop therapeutics solutions. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Mehta VimalCEO and PresidentJun 17 '24Sale1.282,1342,73947,539Jun 18 09:24 PM
Yocca FrankChief Scientific OfficerJun 17 '24Sale1.2837247613,474Jun 18 09:27 PM
Steinhart Richard IChief Financial OfficerJun 17 '24Sale1.263724705,476Jun 18 09:26 PM
Rodriguez JavierSee RemarksJun 17 '24Sale1.263614568,394Jun 18 09:25 PM
Wiley Matthew T.Chief Commercial OfficerJun 17 '24Sale1.262443083,498Jun 18 09:26 PM
O'Neill VincentSee RemarksJun 17 '24Sale1.281551993,524Jun 18 09:25 PM
Mehta VimalCEO and PresidentJun 05 '24Sale1.58126,014199,6197,685,501Jun 06 08:35 PM
Mehta VimalCEO and PresidentJun 04 '24Sale1.63126,014205,5167,811,515Jun 06 08:35 PM
Mehta VimalCEO and PresidentApr 04 '24Sale2.625,26813,82343,564Apr 08 07:32 PM
Steinhart Richard IChief Financial OfficerApr 04 '24Sale2.631,0692,8174,765Apr 08 07:32 PM
Yocca FrankChief Scientific OfficerApr 04 '24Sale2.631,0672,81212,763Apr 08 07:30 PM
Rodriguez JavierSee RemarksApr 04 '24Sale2.641,0122,6677,672Apr 08 07:30 PM
Wiley Matthew T.CHIEF COMMERCIAL OFFICERApr 04 '24Sale2.641,0082,6562,992Apr 08 07:31 PM
O'Neill VincentSee RemarksApr 04 '24Sale2.621654325,408Apr 08 07:32 PM